[Federal Register Volume 62, Number 64 (Thursday, April 3, 1997)]
[Notices]
[Page 15939]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-8453]


-----------------------------------------------------------------------


DEPARTMENT OF JUSTICE

Notice Pursuant to the National Cooperative Research and 
Production Act of 1993; International Pharmaceutical Aerosol Consortium 
for Toxicology Testing of HFA-227 (IPACT-II)

    Notice is hereby given that, on March 6, 1997, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. Sec. 4301 et seq. (``the Act''), the International 
Pharmaceutical Aerosol Consortium for Toxicology Testing of HFA-227 
(``IPACT-II'') has filed written notifications simultaneously with the 
Attorney General and the Federal Trade Commission disclosing a change 
in the name of one of its members. The notifications were filed for the 
purpose of extending the Act's provisions limiting the recovery of 
antitrust plaintiffs to actual damages under specified circumstances. 
Specifically, as the result of a merger, Ciba-Geigy Limited, Basel, 
Switzerland, an original party to IPACT-II, is now known as Novartis 
Pharma, Inc., Basel, Switzerland.
    No other changes have been made in either the membership or planned 
activity of IPACT-II. Membership in this group research project remains 
open, and IPACT-II intends to file additional written notification 
disclosing all changes in membership.
    On February 21, 1991, IPACT-II filed its original notification 
pursuant to Section 6(a) of the Act. The Department of Justice 
published a notice in the Federal Register pursuant to Section 6(b) of 
the Act on April 2, 1991 (56 FR 13489).
    The last notification was filed with the Department on April 15, 
1996. The Department of Justice published a notice in the Federal 
Register on May 14, 1996 (61 FR 24331).
Constance K. Robinson,
Director of Operations, Antitrust Division.
[FR Doc. 97-8453 Filed 4-2-97; 8:45 am]
BILLING CODE 4410-11-M